Neurosigma

Develops and commercializes trigeminal nerve stimulation (TNS) devices for treatment of psychiatric disorders

placeLos Angeles, California, United States calendar_todayFounded 2008 groups8 employees language neurosigma.com

Registered entities

Innovation

16 patent families (11 granted) — focus: Human necessities; filing pace steady. Cited 1,212 times.

YearFilings
20146
20155
20165
20178
20184
20195
20203
20211
20222
20232
20242
20253

Investor mix

4 investors on record.

Investor typeCountShare
Private equity125%
Other / undisclosed375%
Coming soon